|
ESWI Respiratory Virus Summit 2024
ESWI Summit 2024: What's in the pipeline?
Live attenuated vaccines; NIRSE-GAL: Evaluation of the effectiveness and impact of Nirsevimab in Galicia; and Therapeutics
|
ESWI Respiratory Virus Summit 2024
ESWI Summit 2024: Early Career Scientists
ESWI Summit 2024: Early Career Scientists They each delivered a presentation introducing themselves and their ongoing work on RSV, bringing innovative ideas and making clear calls for action.
|
ESWI Respiratory Virus Summit 2024
ESWI Summit 2024: Diagnostics and Point of Care Testing
Keynote Lecture by Dexter Wiseman, Imperial College London
|
ESWI Respiratory Virus Summit 2024
ESWI Summit 2024: Burden of disease in older adults
Keynote Lecture by Stefan Gravenstein, Brown University
|
ESWI Respiratory Virus Summit 2024
ESWI Summit 2024: Burden of disease in infants
Keynote Lecture by Simon Drysdale, St George's University Hospitals NHS Foundation Trust
Scientific Papers
Article
Influenza vaccination in older adults and patients with chronic disorders: A position paper from the Portuguese Society of Pulmonology, the Portuguese Society of Cardiology, the Portuguese Society of Diabetology, the Portuguese Society of Infectious Disea
Influenza affects millions of people worldwide each year and can lead to severe complications, hospitalizations, and even death, especially among vulnerable populations such as older adults and those with chronic medical conditions.
SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase
Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years
Bivalent mRNA COVID-19 vaccines were recommended in the US for children and adolescents aged 12 years or older on September 1, 2022, and for children aged 5 to 11 years on October 12, 2022.
Vaccination coverage in the EU/EEA during autumn 2023 campaigns
Nearly 20 million people aged 60 years and above received COVID-19 vaccines during the autumn/winter campaign in the EU/EEA, according to a new report from the European Centre for Disease Prevention and Control (ECDC).
How well does a flu vaccine work? DRIVE project evaluates performance
Despite challenging conditions posed by the COVID-19 outbreak, the DRIVE project successfully tested how well various brands of flu vaccines worked across five European countries and a range of age groups.
News
Policy & Recommendations
Data-informed decision-making: Driving life-course immunisation in National Immunisations Programs (NIPs)
CLCI, together with MEP Tomislav Sokol and the European Institute for Innovation through Health Data, has produced a report exploring ways of improving the use of data in national immunisation programme planning.
Public health action needed to mitigate the impact of respiratory pathogens for 2023-24 winter season in Europe
In an epidemiological update, the ECDC urges EU/EEA Member States to strengthen vaccination campaigns and prepare for the possible need to increase emergency department and ICU capacity
